These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 8831730)
1. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Rivory LP; Bowles MR; Robert J; Pond SM Biochem Pharmacol; 1996 Oct; 52(7):1103-11. PubMed ID: 8831730 [TBL] [Abstract][Full Text] [Related]
2. CPT-11 converting enzyme from rat serum: purification and some properties. Tsuji T; Kaneda N; Kado K; Yokokura T; Yoshimoto T; Tsuru D J Pharmacobiodyn; 1991 Jun; 14(6):341-9. PubMed ID: 1783980 [TBL] [Abstract][Full Text] [Related]
3. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Satoh T; Hosokawa M; Atsumi R; Suzuki W; Hakusui H; Nagai E Biol Pharm Bull; 1994 May; 17(5):662-4. PubMed ID: 7920428 [TBL] [Abstract][Full Text] [Related]
5. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. Guichard SM; Morton CL; Krull EJ; Stewart CF; Danks MK; Potter PM Clin Cancer Res; 1998 Dec; 4(12):3089-94. PubMed ID: 9865925 [TBL] [Abstract][Full Text] [Related]
6. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172 [TBL] [Abstract][Full Text] [Related]
7. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092 [TBL] [Abstract][Full Text] [Related]
8. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Humerickhouse R; Lohrbach K; Li L; Bosron WF; Dolan ME Cancer Res; 2000 Mar; 60(5):1189-92. PubMed ID: 10728672 [TBL] [Abstract][Full Text] [Related]
9. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Wadkins RM; Hyatt JL; Yoon KJ; Morton CL; Lee RE; Damodaran K; Beroza P; Danks MK; Potter PM Mol Pharmacol; 2004 Jun; 65(6):1336-43. PubMed ID: 15155827 [TBL] [Abstract][Full Text] [Related]
10. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Wadkins RM; Morton CL; Weeks JK; Oliver L; Wierdl M; Danks MK; Potter PM Mol Pharmacol; 2001 Aug; 60(2):355-62. PubMed ID: 11455023 [TBL] [Abstract][Full Text] [Related]
11. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4. Sai K; Kaniwa N; Ozawa S; Sawada JI Drug Metab Dispos; 2001 Nov; 29(11):1505-13. PubMed ID: 11602529 [TBL] [Abstract][Full Text] [Related]
12. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. Dodds HM; Tobin PJ; Stewart CF; Cheshire P; Hanna S; Houghton P; Rivory LP J Pharmacol Exp Ther; 2002 Nov; 303(2):649-55. PubMed ID: 12388647 [TBL] [Abstract][Full Text] [Related]
13. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009 [TBL] [Abstract][Full Text] [Related]
14. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Slatter JG; Su P; Sams JP; Schaaf LJ; Wienkers LC Drug Metab Dispos; 1997 Oct; 25(10):1157-64. PubMed ID: 9321519 [TBL] [Abstract][Full Text] [Related]
15. Determination of drug interactions occurring with the metabolic pathways of irinotecan. Charasson V; Haaz MC; Robert J Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202 [TBL] [Abstract][Full Text] [Related]
16. Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Khanna R; Morton CL; Danks MK; Potter PM Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Danks MK; Morton CL; Pawlik CA; Potter PM Cancer Res; 1998 Jan; 58(1):20-2. PubMed ID: 9426050 [TBL] [Abstract][Full Text] [Related]
18. Metabolism of CPT-11. Impact on activity. Rivory LP Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896 [TBL] [Abstract][Full Text] [Related]
19. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905 [TBL] [Abstract][Full Text] [Related]
20. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Senter PD; Beam KS; Mixan B; Wahl AF Bioconjug Chem; 2001; 12(6):1074-80. PubMed ID: 11716702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]